Sandra E. Burke's research while affiliated with Abbott Laboratories and other places

... Five LOE 3 good-quality studies supported the PICO question. [8][9][10][11][12] These studies varied in the mechanism of arterial thrombosis and the specific thrombolytic. Leach Dogs treated with streptokinase experienced more bleeding from surgical sites (ie, site of femoral vein exposure, thoracotomy, and thrombin injection site in the coronary artery) than saline-treated dogs. ...

... Five LOE 3 good-quality studies supported the PICO question. [8][9][10][11][12] These studies varied in the mechanism of arterial thrombosis and the specific thrombolytic. Leach Dogs treated with streptokinase experienced more bleeding from surgical sites (ie, site of femoral vein exposure, thoracotomy, and thrombin injection site in the coronary artery) than saline-treated dogs. ...

... Pulsed drug release is very important for improving the therapeutic effect of many bioactive molecules, particularly hormones [33][34][35]. However, we require temperature sensitive materials with Ttr above 37 °C so pulsed drug release occurs when temperature rises above this temperature to a maximum of 42 °C, a temperature below the threshold for body heat sensors [36]. ...

... Anticoagulation following thrombolysis is a key component in the maintenance of reperfusion and is standard of care in humans treated with thrombolysis for unstable pulmonary embolism (19). Though there are no comparable studies involving venous thrombosis, numerous canine coronary artery reperfusion studies have documented that anticoagulation has a favorable effect not only on time to thrombolysis but also in delaying or preventing reocclusion after successful thrombolysis (22)(23)(24)(25). The prolongation of aPTT out of range was the obvious reason for discontinuation of heparin therapy as one would expect that therapeutic anticoagulation had been achieved and risk of bleeding was high. ...

... New strategies to increase the likelihood of complete and partial recanalization are justified because unsatisfactory recanalization rates have been reported with intravenous rt-PA alone [4][5][6][7][8][9]. Anticoagulation (AC) therapy, concomitant to rt-PA treatment, with either unfractionated heparin or low molecular weight heparin (LMWH) could potentially decrease reocclusion, as well as increase recanalization rates [10]. ...

... Two different subtypes of development of ischaemia / reperfusion injury. ET receptors, ET and ET , have been characterised and A monoclonal antibody against ET-1 (AwETN40) was A B cloned [8] [9]. ET and ET receptors located on vascular initially used to elucidate the pathophysiological role of A B smooth muscle mediate vasoconstriction, whereas ET endogenous ET-1. ...

... 3,7 Given the absence of a further rise in ET-1 during sitaxentan, our data do not support the possibility that blocking irreversible ET A receptor binding additionally increases ET-1. [30][31][32][33][34] VEGF stimulates endothelial NO production by, among other factors, increased expression of the gene encoding the endothelial NO synthase. In line with this, previous studies have shown that VEGF inhibition is associated with reduced NO production. ...

... Our conclusion that the increased neointima formation in mice with End.LepR deletion may be the result of increased endothelial ET-1 release is supported by previous studies showing that exogenous ET-1 administration dose dependently enhances neointima formation, 36 whereas antagonization of ET receptors effectively reduced intimal hyperplasia in experimental models of vascular injury. [37][38][39] Furthermore, deletion of ET-1 selectively in ECs was shown to reduce neointima formation, vascular adhesion molecule expression, and SMC proliferation, 40 whereas endothelial ET-1 overexpression was associated with vascular hypertrophic remodeling and endothelial dysfunction. 34 Increased local ET-1 expression has been reported in human coronary atherosclerotic plaques, 41 and higher ET-1 and ET-1 receptor expression levels, particularly in ECs, has been described in human atherosclerotic lesions. ...

... No trials have compared LIT with IVT directly, but PROACT II had a lower rate of symptomatic intracranial haemorrhage as compared to NINDS trial at 6 hours (10% vs 12%), LIT tends to be efficacious at lower doses as compared to IVT, as seen in the case reported where only 10 lakh units of urokinase produced a dramatic recovery. Experimental evidence from animal experiments in a canine model show that intra arterial (IA) thrombolysis uses 100 times lower dose of lytic agents as compared to IVT and achieve similar levels of lysis [9]. This suggests that systemic effects of lysis, resulting in haemorrhage, are less likely with the IA route of administration. ...

... 322 , 323 Rapamycin has also been shown to reduce intimal thickening in various animal studies of intimal thickening. [324][325][326] Klugherz and colleagues in a randomized, blinded, prospective study, investigated the efficacy of a sirolimus-eluting stent in rabbit iliac arteries. 327 Sirolimus levels in whole blood peaked at 1 hour post-insertion and fell below quantifiable levels by 72 hours, but a prolonged intramural arterial deposition was confirmed for the duration of the study. ...